A mosquito-borne disease associated with birth defects. Since 1952, Zika outbreaks have been reported in tropical Africa, Southeast Asia, the Pacific Islands, and, in 2015, in the Americas. According to the WHO, there is scientific consensus that Zika virus (ZIKV) is a cause of microcephaly and Guillain-Barré syndrome.
VLA1601 – Valneva’s Zika virus development program that remains on hold
- VLA1601 is a highly purified inactivated vaccine candidate against the Zika virus, developed using the same manufacturing platform as Valneva’s Japanese encephalitis vaccine
- Valneva has concluded the Phase 1 trial and the results obtained will allow the Company to design a Phase 2 trial if it chooses to continue this program.
- Valneva currently has this program on hold, as cases of Zika have significantly declined since 2016. Valneva has chosen to prioritize its development programs to focus on viruses that are currently a greater health crisis, but may choose to reactivate this program in the future if warranted.
Additional information about Zika: